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Levofloxacin is a synthetic broad-spectrum antibacterial agent for oral or intravenous administration. Chemically, levofloxacin is
the levorotatory isomer (L-isomer) of racemate ofloxacin, a fluoroquinolone antibacterial agent. Quinolone derivatives rapidly and
specifically inhibit the synthesis of bacterial DNA. Levofloxacin has in vitro activity against a broad range of aerobic and anaerobic
Gram-positive and Gram-negative bacteria. However, formulation of combined poloxamers thermoregulated (as Pluronic F127)
and levofloxacin for use in multiresistant bacterial treatment were poorly described in the current literature. Thus, the aim of the
present work is to characterize poloxamers for levofloxacin controlled release and their use in the treatment of multidrug bacterial
resistance. Micelles were produced in colloidal dispersions, with a diameter between 5 and 100 nm, which form spontaneously from
amphiphilic molecules under certain conditions as concentration and temperature. Encapsulation of levofloxacin into nanospheres
showed efficiency and enhancement of antimicrobial activity against Escherichia coli, Pseudomonas aeruginosa, and Klebsiella
pneumoniae when compared with only levofloxacin. Furthermore, all formulations were not cytotoxic for NIH/3T3 cell lineage.
In conclusion, poloxamers combined with levofloxacin have shown promising results, better than alone, decreasing the minimal
inhibitory concentration of the studied bacterial multiresistance strains. In the future, this new formulation will be used after being
tested in animal models in patients with resistant bacterial strains.
1. Introduction
In recent years, bacterial resistant infections have become
a global health challenge and are threatening the health of
societies [1–4]. Due to the emergence of resistant infections,
existing antibacterial drugs have become less effective or
even ineffective; this has led to the development of new
antibacterial drugs [1]. Also, quinolones are one of the most
commonly prescribed classes of antibacterials in the world
and are used to treat a variety of bacterial infections in
humans [5].
The founding member of the quinolone drug class,
nalidixic acid, is a naphthyridine that was first isolated by
George Lesher and colleagues in 1962 as a byproduct of
chloroquine synthesis [5, 6]. Nalidixic acid was introduced
into the clinic in the 1960s for the treatment of uncomplicated
urinary tract infections caused by enteric bacteria [5, 7]. By
the 1970s, several first-generation quinolones, oxolinic acid
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being themost notable, had been synthesized and introduced
into the clinic [5, 7–10].
Quinolones were a little-used drug class until the early
1980s, when a second generation of compounds was devel-
oped [5, 7–10]. These newer drugs, highlighted by nor-
floxacin, ciprofloxacin, and ofloxacin, displayed considerably
improved activity against gyrase, greater penetration into
Gram-positive organisms, and enhanced pharmacokinetics
and pharmacodynamics [5]. The most critical changes to
the quinolone skeleton were the introduction of a fluorine
at position C6 and a major ring substituent (piperazine or
methylpiperazine) at C7 [5, 7–10]. Because of the inclusion of
the fluorine, quinolones are often termed “fluoroquinolones”
[5].
Norfloxacin is considered to be the first broad-spectrum
quinolone and was utilized to a far greater extent than
nalidixic acid [5, 7–10]. Unfortunately, because of low serum
levels and poor tissue penetration, norfloxacin was still
confined to use for the treatment of urinary tract infections
and sexually transmitted diseases [5]. Ciprofloxacin was the
first quinolone that displayed significant activity outside of
the urinary tract [5, 7–10]. After more than 20 years in
clinical use, ciprofloxacin remains one of themost commonly
prescribed antibacterial drugs and is used to treat a variety
of Gram-negative and, to a lesser extent, Gram-positive
infections [11–13].
The clinical success of ciprofloxacin spawned an array of
newer-generation quinolones that displayed an even broader
spectrum of activity, especially against Gram-positive species
[5, 7–10]. Levofloxacin, moxifloxacin, and sparfloxacin have
enjoyed the most success and display good activity against
Gram-positive respiratory tract infections. Furthermore, the
pharmacokinetics of levofloxacin are advantageous com-
pared to those of other members of the drug class, and
treatment requires only a single pill per day [5, 14, 15].
Levofloxacin is a member of the fluoroquinolone class of
antibacterial agents withmicrobiological activity against clin-
ically relevant bacteria that cause respiratory, skin and skin
structure, and genitourinary tract infections [15]. Chemically,
this antibiotic is a chiral fluorinated carboxyquinolone, which
is the pure (−)-(S)-enantiomer of the racemic drug substance
ofloxacin.
The chemical name is (−)-(S)-9-fluoro-2,3-dihydro-3-
methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-
de]-1,4-benzoxazine-6-carboxylic acid hemihydrate [16].The
mechanism of action of levofloxacin and other fluoroquinol-
ones antibacterial complexes interferes with bacterial DNA
metabolism by inhibiting two bacterial enzymes, DNAgyrase
and topoisomerase IV, which are critical to DNA replication,
transcription, repair, and recombination [15]. Their primary
targets against Gram-positive and Gram-negative bacteria
are bacterial topoisomerase IV and DNA gyrase, respectively
[15, 17].
Not surprisingly, the number of quinolone-resistant bac-
teria is rising.This can occur during handling, especially with
Pseudomonas infection, which is more common if the patient
previously received drugs and in blood with nonenough dose
for winner infection [18, 19]. For S. aureus and P. aeruginosa, a
singlemutation is enough.More than onemutation is needed
for E. coli to become resistant to quinolone [20, 21].
Due to the development of antibiotic resistance and the
outbreak of infectious diseases caused by resistant pathogenic
bacteria, pharmaceutical companies and researchers are
now searching for new unconventional antibacterial agents.
The demand for individualized therapy and lower risks of
adverse effects has always been a goal for health profes-
sionals. Besides, new pharmaceutical formulations seeking
to increase efficiency and reduce drug toxicity are currently
being researched [22].
Polymers are the substances of high molecular weight
having repeatingmonomer units [23].They arewidely used in
pharmaceutical systems as suspending, adjuvants, adhesives,
emulsifying agents, and coating material for controlled and
site specific drug delivery systems [23]. Polymer molecules
may be branched or linear and separate linear or branched
chains may be joined by crosslinks [23]. The chemical reac-
tivity of polymers depends upon the chemistry of monomer
units but their properties depend to a large extent on the
way of arrangement of the monomers [23]. Polymers having
identical monomeric units are referred to as homopolymers;
those formed from more than one monomer type are called
copolymers [23]. Arrangements of various monomers units,
say A and B, lead to formation of varieties of copolymers [23].
The copolymers may be described as alternating copolymers,
graft copolymers, or block copolymers [23]. Pluronic is one of
the most widely used block copolymers and forms heterogels
[23–25].
Poloxamers are interesting copolymers as a nanocarrier
having amphiphilic characters [23]. Due to large solubility
differences between hydrophobic and hydrophilic moieties,
in aqueous medium, they are able to self-assemble into
polymeric micelles characterized by mesoscopic size range
[23]. These micelles consist of water-insoluble cores and
water-soluble shells [23]. Depending on blocks length, the
core can assemble into various supramolecular structures
characterized by different morphologies [23, 26–28].
Currently, the potential applications of nanoparticles in
advanced materials are being explored and are considered
a key technology for the future [12, 29–31]. In this work,
micelles were produced in colloidal dispersions using polox-
amers, with a diameter between 5 and 100 nm, which form
spontaneously from amphiphilic molecules under certain
conditions as concentration and temperature [32, 33]. Due
to their small size (<100 nm), the micellar carriers have
a high penetration capacity in different tissues such as
vascular endothelium and oral, nasal, and ocular mucosa
[34]. Among the constituents of micellar systems, those of
the block copolymer class of poloxamers stand out (Lutrol,
Pluronic, Synperonic, andTetronic).These units determine
the amphiphilic character of these molecules characterizing
them also for different hydrophilic-lipophilic balance [35].
Furthermore, we investigated for the first time the effect of
encapsulation of levofloxacin for controlled release and we
verify the effectiveness of this process in the resistance of
multidrug bacterial strains.
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F1 PL 407 (8%) PL L-81 (2%)
F2 PL 108 (8%) PL L-81 (2%)
F3 PL 407 (8%) —
F4 PL 108 (8%) —
PL 407 (Pluronic F127); PL 108 (Pluronic 108); and PL L-81 (Pluronic L-81).
2. Material and Methods
2.1. Formulation of Combined Poloxamers Thermoregulated.
ThePluronic F 108NF Prill Poloxamer 338 (PL 338, molecular
weight: 14,600Da), the Pluronic F 127NF Prill Poloxamer
407 (PL 407, molecular weight: 12,600Da), and the Pluronic
L-81 (L-81, molecular weight: 2,750Da) were products of
BASF Corp. (Ludwigshafen am Rhein, Germany) purchased
from Sigma-Aldrich (St. Louis, MO, USA). Levofloxacin
(analytical reference material, molecular weight: 361.37Da),
methylthiazolyldiphenyl-tetrazolium bromide (MTT, molec-
ular weight: 414.32), Brain Heart Infusion Agar (BHI Agar),
and Mueller Hinton Broth were purchased from Accume-
dia (Neogen Corporation, Lansing, MI, USA). RPMI-1640
medium, fetal bovine serum, antibiotic/antimycotic solution
(with 100UI⋅mL−1 penicillin and 100 𝜇g⋅mL−1streptomycin
sulfate), PBS 1x with antibiotic/antimycotic solution, and
Trypsin-EDTA were purchased from Cultilab Laboratory
Materials for Growing Mobile (Campinas, Sa˜o Paulo, Brazil).
All other reagents were of analytical grade. Deionized water
(Purelab Option-Q, ELGA LabWater, High Wycombe, UK)
was used for all experiments [36].
2.2. Production of Polymeric Nanoparticle with or without
Levofloxacin. Polymeric nanoparticle with or without lev-
ofloxacin was prepared in accordance with the cold method
described by Schmolka [36, 37]. Before the incorporation
of levofloxacin in the polymeric nanoparticle, different solu-
tions containing PL 407 (Formulation F3, Table 1) and PL
338 (Formulation F4, Table 1) alone or in binary systems
with L-81 (Formulations F1 and F2, Table 1) were dispersed
in deionized water for 3 hours at 4∘C under magnetic
stirring (100 rpm). After complete dissolution of poloxamers
in deionized water, levofloxacin (0.1mg⋅mL−1) was dispersed
in some formulations (F1-L, F2-L, F3-L, and F4-L, Table 1) for
3 hours at 4∘C under magnetic stirring (100 rpm) [36, 37].
2.3. Size, Polydispersity Index, and Zeta Potential Analyses.
Dynamic light scattering was performed according to dos
Santos et al. [36]. Dynamic light scattering was used to
determine the polymeric diameter, polydispersity index, and
zeta potential.Measurementswere performedusing a particle
analyzer, ZetaSizerNanoZS (Malvern,UK), at a fixed angle of
173∘ and temperatures of 25∘Cand 37∘C [36]. All formulations
were prepared in deionized water and were filtered using
a polycarbonate membrane (pore 0.22𝜇m). Zeta potential
values for all formulations were also measured in deionized
water adjusting conductivity (50 𝜇S⋅cm−1) and were calcu-
lated from the electrophoretic mobility using the Helmholtz-
Smoluchowski equation. The analyses were performed using
the software included in the system [13]. All experimentswere
executed in triplicate.
2.4. Permeation Experiments. Permeation studies of lev-
ofloxacin and levofloxacin-loaded polymeric micelles were
carried out in Franz diffusion cells (DISA, Milan, Italy) with
0.6 cm2 permeation area and a receiver compartment of
4.2mL in volume.Themucosa wasmimicked over a 0.45mm
cellulose filter (connective side of tissue facing themembrane
filter) because of its fragility, avoiding any damage that could
alter permeation parameters without altering levofloxacin
transport. F1-L, F2-L, F3-L, and F4-L were applied in infinite
dose conditions (1.76 g⋅cm−2) in the donor compartment.The
receptor chambers were filled with NaCl 154mM solution
containing HEPES 20mM, pH 7.4, magnetically stirred at
37∘C.
Permeation experiments were performed in no occlusive
conditions during a period of 24 hrs. Samples (1mL) were
periodically withdrawn from the receptor phase, analyzed by
spectrophotometer, and replaced with fresh receptor solution
in equal volumes. The flux of drug was calculated from the
slope of the linear portion of the curve (cumulative amounts
of levofloxacin transported across the mucosa per unit of
area × time). Lag time was obtained from the interception
to the time axis. The permeability coefficient was calculated
according to [38]
𝐽 = 𝑃 × 𝐶
𝑑
, (1)
where J (𝜇g⋅cm−2⋅h−1) is levofloxacin flux across the skin, P
(cm⋅h−1) is the permeability coefficient, and𝐶
𝑑
is levofloxacin
concentration in the donor compartment (𝜇g⋅cm−3).
2.5. Biological In Vitro Assays
2.5.1. Antimicrobial Susceptibility Testing. An in vitro test
using bacterial Gram-positive andGram-negative strains was
performed (Table 2). The antibacterial activity was initially
determined using the double layer agar diffusion method
and then the minimum inhibitory concentration (MIC) was
determined for susceptible bacteria. Some resistant bacterial
strains used in this work were kindly donated by Professor
Dr. Ana Lu´cia da Costa Darini (Faculty of Pharmaceutical
Sciences of Ribeira˜o Preto, Sa˜o Paulo, Brazil).
2.5.2.Microdilution Test toDetermine theMinimum Inhibitory
Concentration (MIC). Stock solutions of each formulation
were prepared before the experiment. The final concen-
trations of these formulations tested ranged from 0.15 to
80 𝜇g⋅mL−1. This experiment was realized in 96-well plate
and all analyses were based on the Fifteenth Informational
Supplement of the Clinical Laboratory [39, 40] and Standards
Institute.
Before the MIC experiment, the strains of interest were
inoculated into BHI agar and incubated at 37∘C for 16–24 h
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Table 2: Bacterial strain, characteristics, and origin of all bacteria
studied in this work.
Strain Characteristic Origin
ATCC
129214 Escherichia coli ATCC 129214 ATCC
CS1 Escherichia coli clinical isolation LABIOTEC
CS2 Escherichia coli clinical isolation LABIOTEC
CS3 Escherichia coli clinical isolation LABIOTEC
37 JF Pseudomonas aeruginosa 37 JF LEBEM
24 JF Pseudomonas aeruginosa 24 JF LEBEM
76 JF Pseudomonas aeruginosa 76 JF LEBEM
ATCC
27853 Pseudomonas aeruginosa ATCC 27853 ATCC
CS4 Pseudomonas aeruginosa clinicalisolation LABIOTEC
ATCC
700603 Klebsiella pneumoniae ATCC 700603 ATCC
CS5 Klebsiella pneumoniae clinical isolation LABIOTEC
CS6 Klebsiella pneumoniae clinical isolation LABIOTEC
CS7 Klebsiella pneumoniae clinical isolation LABIOTEC
ATCC
25922 Staphylococcus aureus ATCC
BEC Staphylococcus aureus Brazilianepidemic clone LABIOTEC
LEBEM: Special Laboratory of Bacteriology and Molecular Epidemiology,
Department of Clinical, Toxicological and Bromatological Analysis, Sa˜o
Paulo State University, USP, Ribeira˜o Preto.
ATCC: American Type Culture Collection.
LABIOTEC: Biotechnology Laboratory, Campinas State University (UNI-
CAMP), Campinas, SP, Brazil.
[41, 42]. On the next day, three to five well-isolated colonies of
the samemorphological type were collected and resuspended
in 1mL of sterile saline (0.9%) until final concentration of
1.5 × 108 colony-forming units (CFU)mL−1 (0.5 McFarland
standard, Probac, Sa˜o Paulo, Brazil). Then, the bacterial
suspension was diluted in each well of 96-well plate to a final
concentration per well of 1 × 105 CFU⋅mL−1 [39].
Next, the dilutions of all concentrations of all formula-
tions were added in 96-well plate to a final volume of 0.1mL.
The positive (levofloxacin) control was prepared to a final
volume 0.1mL with 1 × 105 CFU⋅mL−1 bacteria. Negative
control was prepared with Mueller Hinton Broth without
bacteria. The 96-well plate was incubated in ambient air at
37∘C for 16–20 h. This experiment was run in triplicate for
each strain and for controls [39].
2.6. Cytotoxic Activity
2.6.1. Cell Culture. Wepurchasedmouse fibroblasts NIH/3T3
(ATCC CRL-1658) cell lines from American Type Culture
Collection (ATCC) CCL-1658. We chose the NIH/3T3 cells
because they are widely used as an in vitro model for a
tissue model. Therefore, if the material tested is cytotoxic
on this cell, its use in therapy is discouraged [43–45]. This
cellular lineage was grown in plastic flasks (25 cm2) with
RPMI 1640 medium, supplemented with 10% inactivated
fetal bovine serum and 1% antibiotic/antimycotic solution
[43]. The cultures were incubated at 37∘C in an atmosphere
containing 5% CO
2
[43]. Medium was changed every 48 h,
and when the culture reached confluence, the subculture was
treated with Trypsin-EDTA, until complete release of the
cells. The released cells were transferred to a new plastic flask
or 96-well plates [43–45].
2.6.2. MTT Reduction Assay [43]. Before testing, we dis-
persed different concentrations of all formulations in cul-
ture medium without fetal bovine serum and antibi-
otic/antimycotic solution. We plated NIH/3T3 cells on 96-
well plates [43–45]. We used 1 × 105 cells⋅mL−1 to 1 × 107
cells⋅mL−1 per well [43]. After this, we incubated the plate at
37∘C, in a humidified incubator with 5% CO
2
, for 24 h [43].
Then, the medium was replaced and the test repeated with
different formulations concentrations in the range between 5
and 200𝜇g⋅mL−1, which was added to the wells in triplicate
for each concentration. We used DL50 to define the CCN
cytotoxicity (50% of the cells died) [43–45].
After 24 h of incubation, we removed the medium con-
taining the formulations and washed each well 3 times with
0.1mL of PBS Buffer 1x (137mMNaCl, 10mMphosphate, and
2.7mM KCl, at pH of 7.4) [43]. Next, 0.2mL of RPMI 1640
medium (without FBS and antibiotic/antimycotic solution)
containing the dye MTT (0.5mg⋅mL−1) was added [43, 44].
After incubation for 3 h at 37∘C, we removed the medium
with dye and carefully added 0.2mL of ethanol to solubilize
the blue formazan (yielded from MTT reduction by viable
cells) [43, 45]. The plates were shaken for 10min, and the
absorbance for each well was read in a spectrophotometer,
ELx800 Absorbance Microplate Reader (BioTek, USA), at
𝜆 = 570 nm. The values were expressed as percentages of
MTT reduction compared to the control, where cells were not
exposed to test agents [43, 46, 47].
2.7. Statistical Evaluation. Statistical analysis was performed
using GraphPad Prism version 4.03. All experiments were
conducted in triplicate and the results were expressed as
the means ± standard deviation (SD). Data from each assay
were analyzed statistically by ANOVA.Multiple comparisons
among groups were determined with the Tukey test. Differ-
ences were considered significant when the 𝑝 value was less
than 0.05 [43–45].
3. Results and Discussion
Antibiotics are among the most important tools in medicine,
but their efficacy is threatened by the evolution of resistance
[11]. Since the earliest days of antibiotics, resistance has
been observed and recognized as a threat; today, many first-
generation drugs are all but ineffective [11]. We have thus
far avoided a crisis through the continued modification of
existing compounds and the discovery of new antibiotic
classes [11] as well as the use of nanoparticles to engage and
load this antibiotic, within this class of new antibiotics that
include levofloxacin.
Levofloxacin is a broad-spectrum antibiotic of the fluo-
roquinolone drug class, mainly acting against Gram-positive
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and atypical agents [48, 49]. This antibiotic works as an
inhibitor of DNA gyrase and topoisomerase IV causing bac-
terial death [50]. Despite their effectiveness, these antibiotics
are commonly associated with undesirable side effects [50–
52], mainly due to a tendency to aromatic stack among
themselves under physiological conditions that reduce their
bioavailability and become toxic [50, 53]. In this sense,
encapsulation in smart nano- andmicrobiopolymeric devices
is a novel technology potentially useful to provide effective
controlled release of the drugs, therefore reducing their toxic
concentrations [50]. Despite these, poloxamers were used in
the nanoencapsulation of levofloxacin.
Among the several delivery systems reported in the lit-
erature, poloxamer- (PL-) based thermoreversible hydrogels
have presented promising results in terms of improvement in
the biopharmaceutical, pharmacodynamic, and pharmacoki-
netic properties of the incorporated drugs [36].
PLs (Pluronic) are copolymers consisting of polyethy-
lene oxide (PEO) and polyoxypropylene oxide (PPO) units
arranged in a basic structure A–B–A or PEO–PPO–PEO
type [36]. Due to differences in the number of PPO and
PEO units, PL monomers have the ability to self-assemble
in micelles, presenting a hydrophobic core surrounded by
a hydrophilic corona [35, 36]. At low temperatures, both
PEO and PPO units are soluble in water [36]. However,
when the temperature rises, the PPO units are dehydrated
and aggregate (micellar core), while the hydrophilic PEO
units (micellar corona) remain hydrated [36]. Subsequently,
these micelles are assembled in different supramolecular
structures such as hexagonal, cubic-ordered phases form-
ing the hydrogels’ organization phases [36]. This reversible
phenomenon is characterized by a temperature range of
sol-gel transition (𝑇sol-gel), since, below this temperature,
the systems remain as fluids and favor the development of
injectable formulations but remain as semisolids close to the
physiological temperature [36, 54–56].
These features associated with the biocompatibility of PL
are essential for the development of delivery systems [36]
for treatment of multidrug-resistant bacteria. In addition, the
use of PL with different hydrophilic-lipophilic balance (HLB)
[36] such as PL 407 and PL 403, PL 407 and PL L-81, PL 108
and PL 403, and PL 108 and PL L-81 as binary systems can be
an interesting alternative to modulate the biopharmaceutical
profile of these formulations [13, 36, 57–59].
The use of PL has been reported in the literature
specifically for diverse types of treatment [36]. Previous
studies showed the increased permeation of lidocaine and
ketoprofen incorporated into PL 407 liposomal hydrogels,
across the swine dural membrane [36, 60–62]. Subsequently,
other studies presented the preparation and characterization
processes of PL 407 hydrogels containing diclofenac [36, 63]
and lidocaine [36, 64–66] as well as their pharmacological
evaluations in animal models [36, 65, 67, 68] and humans
[36, 69, 70].
However, these formulations were addressed for the use
of a single type of PL. Moreover, there are no studies on PL-
based in situ thermogelling hydrogel formulations containing
levofloxacin.Therefore, in this work, we demonstrated for the
first time PL 407 and PL 338 single-type loading levofloxacin
and binary hydrogels composed of PL 407 and PL L-81, PL
338 and PL L-81, PL 108 and PL 403, and PL 108 and PL L-81
loading levofloxacin, reinforcing the importance of this work
in the treatment of resistant bacterial infections, principally
those in skin or exposed tissues.
The particle size ranged from 35 to 380 nm. In Formula-
tions F1 and F2 with and F2 and F4 without levofloxacin, they
decreased in size with increasing temperature. It is suggested
that the increase in temperature caused rearrangement of the
surfactant molecules compacting the micelles. However, in
F5, temperatures of 37∘C resulted in an increase in particle
size in all cases. In Formulation 4 the preparation without
levofloxacin showed a decline in nanoparticle size (Figure 1).
Table 3 presents the micellar mean, hydrodynamic diam-
eter, themean distribution, and zeta potential for the different
systems composed of PL 407 or PL 338 isolated or in
association with PL L-81 at room temperature (25∘C) and
body temperature (37∘C).
At 25∘C, the micellar systems composed of PL 407 and
PL 338 presented a bimodal distribution, as observed by the
twomicellar diameters with∼5-6 nm (relative to the presence
of PL unimers in solution) and ∼40–50 nm. However, the
hydrodynamic diameter analysis, at 37∘C, showed a unimodal
distribution, as a result of the micellar thermoresponsive
self-assemblage observed for PL copolymers, considering the
low polydispersion index (PDI = 0.10–0.12) values. Also, the
presence of levofloxacin (LVF) into the systems changed the
micellar dimensions, shifting the hydrodynamic diameter
(∼350–500 nm) to higher values and reducing zeta potential
(−2 to−16mV), for both temperatures, indicating the possible
insertion of the drug into the micellar system. A similar
pattern was also viewed after the insertion of PL L-81 into
the systems, but the hydrodynamic diameter values presented
a major population of ∼490 nm, probably related to the
formation of PL L-81 aggregates in aqueous solution. PL
L-81 is a copolymer with a longer hydrophobic block, low
molecular weight, and hydrophilic-lipophilic balance (HLB)
value of 2, when compared to PL 407 (HLB = 22) and PL
338 (HLB = 29). The formation of binary systems with PL
407 and PL L-81 was recently described in the literature,
but considering a concentration ratio (in %) of 1 : 10 (PL L-
81 : PL 407) [71]. In this work, we have tested a concentration
ratio (in %) of 1 : 4 (PL L-81 : PL 407), considering the
incorporation of a hydrophobic drug such as levofloxacin
(𝑃octanol/water = 4.3).
Zeta potential is a useful indicator of the surface charge
of the particles.The zeta potential values were used to predict
and control the stability of the formulations. The higher the
zeta potential is, the more likely the formulation is to be
stable because charged particles repel each other and this
force can overcome the natural tendency to aggregation.
The polydispersity index varied from 0.191 to 0.444 and the
data obtained statistically by ANOVA had 𝑝 > 0.05. For
intravenous administration, it is desirable that the present
micellar polydispersity index is lower than 0.2.
The analysis of permeation study through Franz diffusion
cells was shown in Figure 2 whereas the permeation profile
was obtained for levofloxacin across Franz diffusion cells







































Figure 1: Characteristics of formulations in 25∘C and 37∘C: (a) polymeric micelles and (b) fluoroquinolone-loaded polymeric micelles.
Table 3: Hydrodynamic diameter (nm), mean distribution (%), and zeta potential (mV) of micelles composed of PL 407 or PL 108 isolated















F1 5.2 ± 0.139.8 ± 0.9
10.5 ± 0.9
89.5 ± 0.2 −15.30 ± 1.03 21.0 ± 0.6 100 −5.45 ± 0.34
F2 5.6 ± 0.246.0 ± 1.5
10.7 ± 1.1
89.3 ± 1.0 −15.70 ± 1.19 22.5 ± 1.7 100 −14.02 ± 0.54
F3 6.2 ± 0.1467.8 ± 42.1
12.7 ± 0.2
87.3 ± 0.3 −3.62 ± 1.58 482.1 ± 20.2 100 −6.63 ± 0.85
F4 37.0 ± 0.1492.1 ± 0.1
31.7 ± 0.1
62.7 ± 0.2 −2.57 ± 1.31 495.4 ± 3.2 98.3 ± 2.3 −2.54 ± 0.64
F1-L 552.4 ± 43.9 99.2 ± 0.8 −6.03 ± 0.63 333.2 ± 2.6 89.2 ± 12 −2.54 ± 0.64
F2-L 6.2 ± 0.06458.4 ± 19.8
12.8 ± 0.2
87.2 ± 0.2 −16.60 ± 0.43 338.3 ± 6.7 95.8 ± 3.7 −16.60 ± 0.54
F3-L 552.3 ± 44.2 98.7 ± 1.2 −2.49 ± 0.65 539.8 ± 80.6 92.2 ± 7.6 −14.40 ± 0.45
F4-L 580.1 ± 0.1 93.1 ± 5.6 −1.90 ± 0.82 587.5 ± 4.9 93.1 ± 2.4 −6.24 ± 0.65
Note: data presented as mean ± standard deviation (𝑛 = 3/formulation).
from the formulation studies. According to these results, the
presence of poloxamers did not affect levofloxacin liberation.
3.1. Antimicrobial Susceptibility Studies. Nevertheless, the use
of poloxamers, particularly in Formulation 1, showed an
important effect in decreasing theMIC of levofloxacin.These
formulations decreased the MIC in 53.3% of the strains
when compared with only levofloxacin. In other strains, the
result was similar to levofloxacin’s. For the same strains,
Formulations 2, 3, and 4 with levofloxacin decreased theMIC
in 33.3%, 40%, and 40%, respectively.
These results reinforce the hypothesis of the new use
of nanoformulations for controlled delivery of antibiotics
in infections caused by resistant bacteria. Furthermore,
according to the MIC analysis, the preferential effect of these
formulations in Gram-negative strains indicates a possible
interaction of poloxamer preparations with a membrane of
these bacteria (as, e.g., Pseudomonas, E. coli, and Klebsiella
strains used in this work, Tables 2 and 4).
Fluoroquinolone-loaded polymeric micelles reduce
murine fibroblast but not levofloxacin and polymeric
micelles.
In analysis of cytotoxicity in NIH/3T3 murine fibroblast,
the formulations using levofloxacin incorporated in Formu-
lations 1, 2, 3, and 4 presented a low cytotoxic effect.This effect
could be used in the treatment of, for example, burned skin,
helping the removal of damaged tissue and increasing the
penetration of the antibiotic, thus improving the treatment
of possible infections.
From the MTT reduction assay, it was observed that
polymeric micelles (Figure 3(a)) did not affect the viability of
murine fibroblast (NIH/3T3), while this cell was sensitive to
levofloxacin and fluoroquinolone-loaded polymeric micelles
(Figure 3(b)). Formulations 1 and 2 had an IC
50
of around
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Figure 2: Levofloxacin liberation across Franz diffusion cells. L (-
◼-), F1 + L (-e-), F2 + L (-󳵳-), F3 + L (-󳶃-), and F4 + L (-X-) were
carried out in Franz diffusion cells for 24 h, and the concentration
of levofloxacin permeate was calculated. The results represent the
means ± SD.
Table 4: Bacteria susceptibility to antimicrobial agent, levofloxacin,
and the formulation with levofloxacin.
Strain Levofloxacin(L) F1 + L F2 + L F3 + L F4 + L
ATCC
129214 0.15 𝜇g 0.15 𝜇g 0.15 𝜇g 0.15 𝜇g 0.15 𝜇g
CS1 10𝜇g 5 𝜇g 10𝜇g 5𝜇g 5 𝜇g
CS2 10𝜇g 10𝜇g 10𝜇g 10 𝜇g 10𝜇g
CS3 0.3 𝜇g 0.15 𝜇g 0.15 𝜇g 0.3 𝜇g 0.3 𝜇g
37 JF 0.3 𝜇g 0.15 𝜇g 0.15 𝜇g 0.15 𝜇g 0.15 𝜇g
24 JF 0.5 𝜇g 0.15 𝜇g 0.3 𝜇g 0.3 𝜇g 0.3 𝜇g
76 JF 𝑅 𝑅 𝑅 𝑅 𝑅
ATCC
27853 𝑅 10𝜇g 𝑅 𝑅 𝑅
CS4 0.30 𝜇g 0.15 𝜇g 0.30 𝜇g 0.15 𝜇g 0.15 𝜇g
ATCC
700603 0.5 𝜇g 0.15 𝜇g 0.15 𝜇g 0.3 𝜇g 0.3 𝜇g
CS5 𝑅 𝑅 𝑅 𝑅 𝑅
CS6 0.15 𝜇g 0.15 𝜇g 0.15 𝜇g 0.15 𝜇g 0.15 𝜇g
CS7 10𝜇g 10𝜇g 10𝜇g 10 𝜇g 𝑅
ATCC
25922 0.30 𝜇g 0.15 𝜇g 0.15 𝜇g 0.15 𝜇g 0.15 𝜇g
BEC 5 𝜇g 5 𝜇g 𝑅 5𝜇g 5 𝜇g
𝑅: resistance MIC point.
10 𝜇M; Formulations 3 and 4 and levofloxacin were much
less sensitive; cell viability dropped only 13%, 19%, and 30%,
respectively, in the concentration of 10 𝜇M of levofloxacin.
4. Conclusions
In conclusion, the possible uses of combined formulations
of antibiotics and thermoregulated poloxamers have new




































Formulation 1 + levofloxacin
Formulation 2 + levofloxacin
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Figure 3: Effects of polymeric micelles and fluoroquinolone-loaded
polymeric micelles on BALB/c 3T3 cell viability. BALB/c 3T3 cells
were treated with different concentrations of polymeric micelles (a)
and fluoroquinolone-loaded polymericmicelles (b) for 24 h, and cell
viability was assessed byMTT reduction assay.The results represent
the means ± SD.
perspectives for clinical uses, mainly in the infections in
damaged skin and exposed tissues. New formulations using
combined antibiotics are worth our attention for systemic or
parenteral use.
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